Josh Jennings
Stock Analyst at Morgan Stanley
(2.67)
# 1,889
Out of 4,792 analysts
14
Total ratings
54.55%
Success rate
18.14%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Josh Jennings
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DCBO Docebo | Maintains: Overweight | $49 → $53 | $27.94 | +89.69% | 5 | Nov 10, 2023 | |
| PODD Insulet | Maintains: Outperform | $350 → $300 | $246.90 | +21.51% | 3 | Aug 9, 2023 | |
| BFLY Butterfly Network | Initiates: Outperform | $20 | $1.98 | +912.66% | 1 | Jun 21, 2021 | |
| MDWD MediWound | Initiates: Outperform | $63 | $15.34 | +310.69% | 1 | Sep 28, 2017 | |
| CTSO Cytosorbents | Initiates: Outperform | $7 | $0.97 | +619.28% | 1 | Jun 7, 2017 | |
| EW Edwards Lifesciences | Maintains: Outperform | $43 → $40 | $71.36 | -43.95% | 3 | Dec 7, 2016 | |
Docebo
Nov 10, 2023
Maintains: Overweight
Price Target: $49 → $53
Current: $27.94
Upside: +89.69%
Insulet
Aug 9, 2023
Maintains: Outperform
Price Target: $350 → $300
Current: $246.90
Upside: +21.51%
Butterfly Network
Jun 21, 2021
Initiates: Outperform
Price Target: $20
Current: $1.98
Upside: +912.66%
MediWound
Sep 28, 2017
Initiates: Outperform
Price Target: $63
Current: $15.34
Upside: +310.69%
Cytosorbents
Jun 7, 2017
Initiates: Outperform
Price Target: $7
Current: $0.97
Upside: +619.28%
Edwards Lifesciences
Dec 7, 2016
Maintains: Outperform
Price Target: $43 → $40
Current: $71.36
Upside: -43.95%